Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : AMGN crawled date : 2021 - 04 - 08 save search
BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström’s Macroglobulinemia
Published: 2021-04-08 (Crawled : 12:00) - biospace.com/
BGNE | $131.94 0.06% 0.06% 130K
|
Health Technology
|
| O: 1.06%
H: 0.92%
C: -3.19%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.39%
H: 0.15%
C: -0.89%
brukinsa
BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress
Published: 2021-04-08 (Crawled : 12:00) - biospace.com/
BGNE | $131.94 0.06% 0.06% 130K
|
Health Technology
|
| O: 1.06%
H: 0.92%
C: -3.19%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.39%
H: 0.15%
C: -0.89%
covid phase 2 trial brukinsa
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.